FinZonalExplore Data →
← CompaniesCOMPANY FINANCIAL PROFILE

JOHNSON & JOHNSON

JNJ · CIK 0000200406 · Pharmaceutical Preparations

Last SEC sync: Nov 7, 2026 14:52 UTC

About JOHNSON & JOHNSON

General Johnson & Johnson and its subsidiaries (the Company) have approximately 138,200 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field.

Business information sourced from SEC annual filing filed Feb 11, 2026. Business descriptions reflect the cited filing and may not describe subsequent changes.

Company identification is based on SEC registration information. Financial figures are sourced from SEC filings.

Financial highlights

Latest qualifying annual SEC observations · USD
Revenue$94.19BPeriod Dec. 28, 2025 · 10-K · Filed Feb. 11, 2026
Net Income$26.80BPeriod Dec. 28, 2025 · 10-K · Filed Feb. 11, 2026
Operating Income$21.59BPeriod Dec. 28, 2014 · 10-K · Filed Feb. 24, 2015
Total Assets$199.21BPeriod Dec. 28, 2025 · 10-K · Filed Feb. 11, 2026
Total Liabilities$117.67BPeriod Dec. 28, 2025 · 10-K · Filed Feb. 11, 2026
Cash and Cash Equivalents$19.71BPeriod Dec. 28, 2025 · 10-K · Filed Feb. 11, 2026
Operating Cash Flow$24.53BPeriod Dec. 28, 2025 · 10-K · Filed Feb. 11, 2026
Revenue growth · latest comparable annual periods6.0%
Net profit margin · matching fiscal period28.5%

Historical financial performance

USD billions · Annual SEC observations · Choose a metric

Each metric uses a consistent SEC accounting concept when available. Fiscal year-end dates may differ across metrics. Negative values are displayed with a minus sign.

Annual financial history

USD · Exact fiscal period ends
Period endedRevenueNet incomeOperating incomeAssetsLiabilitiesCashOperating cash flowNet margin
Dec. 28, 2025$94.19B$26.80B—$199.21B$117.67B$19.71B$24.53B28.5%
Dec. 29, 2024$88.82B$14.07B—$180.10B$108.61B$24.10B$24.27B15.8%
Dec. 31, 2023$85.16B$35.15B—$167.56B$98.78B$21.86B$22.79B41.3%
Jan. 1, 2023$79.99B$17.94B—$187.38B$110.57B$12.89B$21.19B22.4%
Jan. 2, 2022$78.74B$20.88B—$182.02B$108.00B$14.49B$23.41B26.5%
Jan. 3, 2021$82.58B$14.71B—$174.89B$111.62B$13.98B$23.54B17.8%
Dec. 29, 2019$82.06B$15.12B—$157.73B$98.26B$17.30B$23.42B18.4%
Dec. 30, 2018$81.58B$15.30B—$152.95B$93.20B$18.11B$22.20B18.8%

A dash indicates unavailable or nonmatching period data. Figures are SEC observations, not estimates.

Company information

Registered name
JOHNSON & JOHNSON
Ticker symbol
JNJ
CIK
0000200406
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC SIC code
2834
Fiscal year end (MMDD)
0103
Last SEC synchronization
Nov 7, 2026 14:52 UTC
Headquarters / business address
ONE JOHNSON & JOHNSON PLZ
NEW BRUNSWICK, NJ 08933
Mailing address
ONE JOHNSON & JOHNSON PLZ
NEW BRUNSWICK, NJ 08933
Business phone
732-524-2455

Company contact information is drawn from SEC submissions, where reported, and may not reflect current operating locations. Last company information check: Nov 7, 2026 20:21 UTC. Official website, business descriptions and executive details require separate verification.

Latest SEC filings

Browse filings →
FormFiledReport periodOfficial source
8-KOct. 13, 2026Oct. 13, 2026View SEC filing ↗
8-KAug. 4, 2026Aug. 4, 2026View SEC filing ↗
8-KJuly 29, 2026July 29, 2026View SEC filing ↗
8-KJuly 28, 2026July 27, 2026View SEC filing ↗
8-KJuly 15, 2026July 15, 2026View SEC filing ↗
8-KApril 28, 2026April 23, 2026View SEC filing ↗
8-KApril 14, 2026April 14, 2026View SEC filing ↗
8-KJan. 21, 2026Jan. 21, 2026View SEC filing ↗
8-KOct. 14, 2025Oct. 14, 2025View SEC filing ↗
8-KSept. 9, 2025Sept. 8, 2025View SEC filing ↗
8-KJuly 16, 2025July 16, 2025View SEC filing ↗
8-KJune 10, 2025June 10, 2025View SEC filing ↗
8-KApril 30, 2025April 24, 2025View SEC filing ↗
8-KApril 15, 2025April 15, 2025View SEC filing ↗
8-KApril 3, 2025March 31, 2025View SEC filing ↗
8-KFeb. 26, 2025Feb. 26, 2025View SEC filing ↗
8-KFeb. 20, 2025Feb. 20, 2025View SEC filing ↗
8-KJan. 22, 2025Jan. 22, 2025View SEC filing ↗
8-KOct. 15, 2024Oct. 15, 2024View SEC filing ↗
8-KSept. 20, 2024Sept. 20, 2024View SEC filing ↗

Financial data is provided for informational purposes, not investment advice. Observations may include restatements; review original SEC filings before making decisions.